We can’t show the full text here under this license. Use the link below to read it at the source.
Understanding the Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Heart Failure.
How Drugs Activating GLP-1 Receptors May Help Treat Heart Failure
AI simplified
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve quality of life and exercise capacity in patients with heart failure.
- GLP-1 RAs have shown potential benefits in reducing body weight and improving insulin sensitivity.
- These agents may possess anti-inflammatory properties and enhance endothelial function.
- Recent trials indicate that GLP-1 RAs could reduce major adverse cardiovascular events.
- Improvements were observed in plasma markers such as N-terminal pro B-type natriuretic peptide, troponin, and C-reactive protein.
- Further research is necessary to evaluate the cardiovascular effects of GLP-1 RAs in a wider array of heart failure patients.
AI simplified